Eksp Klin Farmakol. 2010 Sep;73(9):2-5.

[Effect of new polyprenol drug ropren on anxiety-depressive-like behavior in rats with experimental Alzheimer disease].

[Article in Russian]

Fedotova IuO, Sultanov VS, Kuznetsova NN, Roshchin VI, Nikitina TV.

Influence of the chronic administration of ropren (Trademark)--a plant preparation based on the neutral fraction of extract of spruce and pine needles--on affective status in male rats with amyloid peptide (Abeta(25-35)) induced amnesia has been studied. Ropren was administered per os in a dose of 8.6 mg/kg for 28 days. Anxiety, depressive-like behavior, and behavioral reactions were assessed in the elevated plus maze, forced swimming, and open field tests. The four-week treatment revealed significant anxiolytic and antidepressant effects of the drug. Ropren administration improved various behavioral parameters. The obtained results show that ropren ameliorates behavioral deficits in animal model relevant to Alzheimer's disease and indicate that Ropren is potentially active in the management of affective impairments in the experimental model under consideration. It also has a profound beneficial effect on the anxiety and depressive-like behavior in rats with model Alzheimer's type dementia, and thus may prove to be a novel natural treatment.

PMID:  21086644